Mericitabine

Mericitabine
Clinical data
Trade names	Mericitabine
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate;
CAS Number	940908-79-2 ;
PubChem CID	16122663;
ChemSpider	17279576;
UNII	TA63JX8X52;
KEGG	D10477;
Chemical and physical data
Formula	C18H26FN3O6
Molar mass	399.419 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C(=O)OC[C@@H]1[C@H]([C@@]([C@@H](O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C;
	InChI InChI=1S/C18H26FN3O6/c1-9(2)14(23)26-8-11-13(28-15(24)10(3)4)18(5,19)16(27-11)22-7-6-12(20)21-17(22)25/h6-7,9-11,13,16H,8H2,1-5H3,(H2,20,21,25)/t11-,13-,16-,18-/m1/s1; Key:MLESJYFEMSJZLZ-MAAOGQSESA-N;

Mericitabine (RG-7128) is an antiviral drug, a deoxycytidine analog (a type of nucleoside analog). It was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor, but while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a stand alone agent. However mericitabine has been shown to boost the efficacy of other antiviral drugs when used alongside them, and as most modern treatment regimens for hepatitis C use a combination therapy of several antiviral drugs, clinical trials have continued to see if it can form a part of a clinically useful drug treatment program.[1][2]

References

Gentile, I; Coppola, N; Buonomo, A. R.; Zappulo, E; Borgia, G (2014). "Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus". Expert Opin Investig Drugs. 23 (9): 1211–23. doi:10.1517/13543784.2014.921680. PMID 24848437.
Wedemeyer, H; Forns, X; Hézode, C; Lee, S. S.; Scalori, A; Voulgari, A; Le Pogam, S; Nájera, I; Thommes, J. A. (2016). "Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies". PLoS One. 11 (1): e0145409. Bibcode:2016PLoSO..1145409W. doi:10.1371/journal.pone.0145409. PMC 4713467. PMID 26752189.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Gentile, I; Coppola, N; Buonomo, A. R.; Zappulo, E; Borgia, G (2014). "Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus". Expert Opin Investig Drugs. 23 (9): 1211–23. doi:10.1517/13543784.2014.921680. PMID 24848437.

[2] Wedemeyer, H; Forns, X; Hézode, C; Lee, S. S.; Scalori, A; Voulgari, A; Le Pogam, S; Nájera, I; Thommes, J. A. (2016). "Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies". PLoS One. 11 (1): e0145409. Bibcode:2016PLoSO..1145409W. doi:10.1371/journal.pone.0145409. PMC 4713467. PMID 26752189.

Mericitabine

See also

References